One would think (hope) that question should be moving to the top of the list for the next UniQure earnings call in the Q&A portion w/ analysts. That is, if an analyst report prior to the next UniQure earnings call doesn't specifically address it after the lead-in "we spoke with management...."
I'd definitely think one analyst would be savvy enough to try to pull more color on the FDA steady-state specifics from UniQure in the next earnings call..
Then, of course, the question remains as to how universally applicable that "steady-state as defined by FDA for UniQure's HemoB gene therapy" is w/ respect to what could be applicable to HemoA gene therapy.
I guess that was my long-winded way of saying...we'll see.